Hopeful combo tested for tough liver cancer
NCT ID NCT04301778
Summary
This study tested whether adding two immunotherapy drugs (durvalumab and SNDX-6532) after a standard liver-directed treatment could help control a hard-to-treat liver cancer. It involved 5 patients whose cancer could not be surgically removed. The main goals were to see if the treatment was safe and if it could shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE INTRAHEPATIC CHOLANGIOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
Conditions
Explore the condition pages connected to this study.